X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Olanzapine is an atypical antipsychotic that exerts its action primarily on dopamine and serotonin receptors. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic receptor.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: Olanzapine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2023
Details:
Apixaban is an oral, reversible, and selective active site inhibitor of FXa. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
Lead Product(s): Apixaban
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Apixaban-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Gabapentin inhibits the action of alpha-2-delta-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters. It is indicated for the management of postherpetic neuralgia.
Lead Product(s): Gabapentin
Therapeutic Area: Neurology Product Name: Gabapentin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Canagliflozin inhibits SGLT2 which reduces reabsorption of filtered glucose thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, intestinal absorption of glucose and improves insulin sensitivity.
Lead Product(s): Canagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Canagliflozin/Metformin Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. It is given to treat a rare lung disorder called lymphangioleiomyomatosis which predominantly affects women of childbearing age.
Lead Product(s): Sirolimus
Therapeutic Area: Immunology Product Name: Sirolimus-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Canagliflozin
Therapeutic Area: Endocrinology Product Name: Canagliflozin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistance.
Lead Product(s): Bosentan Hydrate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Bosentan-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Fetzima® generic version (levomilnacipran) is an oral extended release capsule which selectively inhibits serotonin and norepinephrine reuptake (SNRI) and it has shown positive results for the treatment of major depressive disorder (MDD) in adults.
Lead Product(s): Levomilnacipran
Therapeutic Area: Psychiatry/Psychology Product Name: Levomilnacipran-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
Febuxostat is a xanthine oxidase inhibitor, indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol.
Lead Product(s): Febuxostat
Therapeutic Area: Rheumatology Product Name: Zurig
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
Halcion (triazolam) tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep). It works by slowing activity in the brain to allow sleep.
Lead Product(s): Triazolam
Therapeutic Area: Sleep Product Name: Triazolam-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
